6 news items
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
CHRS
23 May 24
dose escalation results are an important milestone as we progress our innovative I-O pipeline. We are very pleased with the safety profile
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA
CHRS
23 May 24
, NASDAQ:CHRS) today announced that senior management will present at the upcoming TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
CHRS
9 May 24
, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
CHRS
8 Apr 24
Coherus is a commercial-stage biopharmaceutical company focused on researching, developing, and commercializing innovative
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
CHRS
13 Mar 24
Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative
4udehqlo0mfzilcnt0ypzgdb p0ljwegob7bgsytuswd47iqqmcp7eze2w
CHRS
4 Mar 24
and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline of tumor microenvironment
- Prev
- 1
- Next